摘要
目的考察便秘型肠易激综合征患者使用利那洛肽缓解功能性便秘症状的疗效、用药后的指标变化以及经济成本,探究利那洛肽治疗功能性便秘的效益性和安全性。方法回顾性收集2019年9月至2022年8月福建医科大学附属福州市第一医院收治的便秘型肠易激综合征患者的临床资料,根据是否使用利那洛肽治疗分为治疗组和对照组,并采用倾向性评分匹配法(PSM)进行匹配。比较两组患者的疗效、不良反应和经济成本。结果共158例便秘型肠易激综合征患者纳入研究,PSM匹配后两组各纳入患者46例。匹配后两组患者的性别、年龄、民族、婚姻状态、工作状态、合并症和医保类型比较差异均无统计学意义(P>0.05)。治疗组患者的功能性便秘改善率显著高于对照组(100.0%vs.89.1%,P=0.021),腹痛缓解率也显著高于对照组(100.0%vs.87.0%,P=0.011),两组患者用药后腹泻发生率差异无统计学意义(2.2%vs.4.3%,P=0.557)。治疗组患者住院天数显著缩短[7(3,12)d vs.10(5,17)d,P=0.012],药品总费用降低[2226(1064,3127)元vs.2095(986,3673)元,P<0.001]。结论利那洛肽治疗便秘型肠易激综合征的疗效良好,并具有一定的安全性,还能在一定程度上减少药品费用。
Objective To investigate the efficacy,the change in indexes and economic cost of linaclotide in relieving functional constipation symptoms in patients with constipation-type irritable bowel syndrome,and to explore the efficacy and safety of linaclotide in the treatment of functional constipation.Methods The clinical data of patients with constipation-type irritable bowel syndrome admitted to Affiliated Fuzhou First Hospital of Fujian Medical University from September 2019 to August 2022 were retrospectively collected.According to whether linaclotide was used,they were divided into treatment group and control group,and matched by propensity score matching(PSM).The efficacy,adverse reactions and economic costs of the two groups were compared.Results A total of 158 patients with constipation-type irritable bowel syndrome were enrolled in the study,and 46 patients in each group were enrolled after PSM matching.After matching,there were no significant differences in gender,age,ethnicity,marital status,work status,comorbidities or type of medical insurance between the two groups(P>0.05).The improvement rate of functional constipation in the treatment group was significantly higher than that in the control group(100.0%vs.89.1%,P=0.021),and the remission rate of abdominal pain was also significantly higher than that in the control group(100.0%vs.87.0%,P=0.011).There was no significant difference in the incidence of diarrhea between the two groups(2.2%vs.4.3%,P=0.557).In the linaclotide treatment group the length of hospital stay was significantly shortened[7(3,12)d vs.10(5,17)d,P=0.012]and the total drug cost reduced[2226(1064,3127)yuan vs.2095(986,3673)yuan,P<0.001].Conclusion Linaclotide can ensure the efficacy and safety in the treatment of constipation-type irritable bowel syndrome,and reduce the drug cost to a certain extent。
作者
戴亨纷
郑彩云
蔡筱蕾
蔡慧美
韩海燕
Dai Hengfen;Zheng Caiyun;Cai Xiaolei;Cai Huimei;Han Haiyan(Department of Pharmacy,Affiliated Fuzhou First Hospital of Fujian Medical University,Fuzhou 350009,China;Department of Gastroenterology,Affiliated Fuzhou First Hospital of Fujian Medical University,Fuzhou 350009,China;Department of Geriatrics,Affiliated Fuzhou First Hospital of Fujian Medical University,Fuzhou 350009,China;Department of Clinical Pharmacy,Affiliated Fuqing Hospital of Fujian Medical University,Fuzhou 350300,China)
出处
《实用药物与临床》
CAS
2023年第7期602-608,共7页
Practical Pharmacy and Clinical Remedies
基金
福建省自然科学基金项目(2021J011304)
福州市卫生健康科技计划项目(2022-S-wq1,2022-S-wr2)
福建医科大学附属福州市第一医院院级科研项目(2022-YJ-02)。
关键词
利那洛肽
便秘型肠易激综合征
功能性便秘
倾向性评分匹配法
Linaclotide
Constipation-type irritable bowel syndrome
Functional constipation
Propensity score matching
